Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316822 · ClinicalTrials.gov registry record · Phase 1
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
A Phase 1 study, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01316822 is a Phase 1 study that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 26 participants.
The verdict
NCT01316822, a Phase 1 study, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase 1 study during which patients with advanced cancer will receive investigational study drug ARRY-382. Patients will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 50 patients from the US will be enrolled in this study.
Interventions
- DRUG ARRY-382, cFMS inhibitor; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316822
The ClinicalTrials.gov registry entry for NCT01316822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARRY-382, cFMS inhibitor; oral is the first listed.
NCT01316822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316822 about?
NCT01316822 is a clinical study titled "A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers". This is a Phase 1 study during which patients with advanced cancer will receive investigational study drug ARRY-382. Patients will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Patients will be fo...
What is the current status of trial NCT01316822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01316822?
The interventions under investigation include: ARRY-382, cFMS inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT01316822?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.